Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCLNASDAQ:AMPHNASDAQ:DYNNASDAQ:TKNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$3.81+1.5%$2.66$1.89▼$4.09$1.13B0.623.42 million shs1.95 million shsAMPHAmphastar Pharmaceuticals$23.18-1.7%$24.73$22.64▼$53.96$1.09B0.72495,165 shs221,782 shsDYNDyne Therapeutics$9.05+1.2%$11.69$6.36▼$47.45$995.72M1.081.82 million shs1.99 million shsTKNOAlpha Teknova$5.22+2.6%$5.92$1.16▼$10.37$278.43M0.33422,842 shs147,080 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics0.00%+5.40%+60.55%+82.06%+40.41%AMPHAmphastar Pharmaceuticals0.00%+0.41%-9.19%-12.91%-39.90%DYNDyne Therapeutics0.00%-5.43%-35.31%+9.30%-73.45%TKNOAlpha Teknova0.00%+2.15%-9.53%+11.54%+331.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCLAbCellera Biologics2.4514 of 5 stars3.41.00.00.03.23.30.0AMPHAmphastar Pharmaceuticals4.3633 of 5 stars3.12.00.03.71.94.21.3DYNDyne Therapeutics3.7768 of 5 stars4.53.00.00.02.93.30.0TKNOAlpha Teknova3.0699 of 5 stars3.53.00.00.03.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.75Moderate Buy$8.33119.01% UpsideAMPHAmphastar Pharmaceuticals 2.25Hold$32.3339.52% UpsideDYNDyne Therapeutics 3.00Buy$41.13354.42% UpsideTKNOAlpha Teknova 3.00Buy$8.5062.84% UpsideCurrent Analyst Ratings BreakdownLatest TKNO, AMPH, DYN, and ABCL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025DYNDyne TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/25/2025DYNDyne TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/24/2025DYNDyne TherapeuticsSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform$13.006/18/2025DYNDyne TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/18/2025DYNDyne TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$46.00 ➝ $32.006/17/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/11/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$37.006/2/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.00 ➝ $34.005/29/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.005/16/2025ABCLAbCellera BiologicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $10.005/12/2025AMPHAmphastar PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$45.00 ➝ $30.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$28.83M39.39N/AN/A$3.58 per share1.06AMPHAmphastar Pharmaceuticals$731.97M1.49$4.99 per share4.64$15.23 per share1.52DYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/ATKNOAlpha Teknova$37.74M7.39N/AN/A$1.55 per share3.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$162.86M-$0.56N/AN/AN/A-737.56%-15.98%-12.38%8/5/2025 (Estimated)AMPHAmphastar Pharmaceuticals$159.52M$2.768.407.046.0419.38%22.20%10.40%8/6/2025 (Estimated)DYNDyne Therapeutics-$317.42M-$3.59N/AN/AN/AN/A-52.83%-48.84%8/11/2025 (Estimated)TKNOAlpha Teknova-$26.75M-$0.48N/AN/AN/A-60.90%-28.48%-19.73%8/12/2025 (Estimated)Latest TKNO, AMPH, DYN, and ABCL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ABCLAbCellera Biologics-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/8/2025Q1 2025TKNOAlpha Teknova-$0.11-$0.09+$0.02-$0.09$9.41 million$9.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A10.1510.15AMPHAmphastar Pharmaceuticals0.802.952.02DYNDyne TherapeuticsN/A20.3520.35TKNOAlpha Teknova0.175.644.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%AMPHAmphastar Pharmaceuticals65.09%DYNDyne Therapeutics96.68%TKNOAlpha Teknova13.81%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%AMPHAmphastar Pharmaceuticals27.10%DYNDyne Therapeutics20.77%TKNOAlpha Teknova12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.42 million212.18 millionOptionableAMPHAmphastar Pharmaceuticals2,02847.14 million34.36 millionOptionableDYNDyne Therapeutics100113.67 million90.06 millionOptionableTKNOAlpha Teknova24053.44 million46.76 millionNot OptionableTKNO, AMPH, DYN, and ABCL HeadlinesRecent News About These CompaniesTradewinds LLC. Raises Stock Position in Alpha Teknova, Inc. (NASDAQ:TKNO)July 6 at 8:48 AM | marketbeat.comMartha J. Demski Sells 8,000 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO) StockJuly 2, 2025 | insidertrades.comAlpha Teknova, Inc. (NASDAQ:TKNO) Director Sells $40,480.00 in StockJuly 1, 2025 | marketbeat.comAlpha Teknova, Inc. (TKNO) Income Statement - Yahoo FinanceJune 28, 2025 | ca.finance.yahoo.comConestoga Capital Advisors LLC Sells 52,070 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO)June 17, 2025 | marketbeat.comAlpha Teknova, Inc. (NASDAQ:TKNO) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comAlpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comTeknova Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comAlpha Teknova (TKNO) Traded Lower on Increased UncertaintyApril 30, 2025 | msn.comAlpha Teknova, Inc. to Report First Quarter Financial Results on May 8, 2025April 24, 2025 | quiverquant.comQTeknova to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | globenewswire.comAlpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation systemMarch 20, 2025 | markets.businessinsider.comTeknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell TherapiesMarch 19, 2025 | markets.businessinsider.comTeknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell TherapiesMarch 19, 2025 | globenewswire.comTeknova, Pluristyx announce collaboration over next-generation cell therapiesMarch 11, 2025 | markets.businessinsider.comTeknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell TherapiesMarch 11, 2025 | globenewswire.comEarnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.67March 8, 2025 | uk.finance.yahoo.comBTIG Reaffirms Their Hold Rating on Alpha Teknova (TKNO)March 6, 2025 | markets.businessinsider.comAlpha Teknova, Inc. (NASDAQ:TKNO) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | msn.comAlpha Teknova’s Earnings Call: Growth Amid ChallengesMarch 5, 2025 | tipranks.comAlpha Teknova, Inc. (TKNO) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendTop Steel Picks for the Coming Infrastructure BoomBy Chris Markoch | June 25, 2025View Top Steel Picks for the Coming Infrastructure BoomTKNO, AMPH, DYN, and ABCL Company DescriptionsAbCellera Biologics NASDAQ:ABCL$3.80 +0.06 (+1.47%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$3.78 -0.02 (-0.53%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Amphastar Pharmaceuticals NASDAQ:AMPH$23.18 -0.41 (-1.72%) Closing price 07/3/2025 03:50 PM EasternExtended Trading$23.18 0.00 (0.00%) As of 07/3/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Dyne Therapeutics NASDAQ:DYN$9.05 +0.11 (+1.23%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$8.99 -0.06 (-0.62%) As of 07/3/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Alpha Teknova NASDAQ:TKNO$5.22 +0.13 (+2.55%) As of 07/3/2025 01:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.